Cuneo et al. demonstrated that crizotinib, a c-Met inhibitor, radio-sensitized KRAS-mutant CRC cell lines, suggesting that crizotinib can be prescribed to patients with CRC requiring radiotherapy [35]. The gene discussed is MET; the disease is colorectal carcinoma.